Liquidia CorporationLQDA
Price as of · delayed, not real-time
Liquidia Corporation is a late-stage biopharmaceutical company focused on the development and commercialization of novel therapies for patients with rare pulmonary diseases. Its lead product candidate, YUTREPIA (treprostinil) inhalation powder, is designed to improve upon current prostacyclin therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is advancing its pipeline and preparing for potential regulatory milestones, with a focus on addressing unmet medical needs in these underserved patient populations.
Congressional Interest in Liquidia Corporation (LQDA)
No congressional trades have been disclosed for Liquidia Corporation (LQDA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Who in Congress Is Trading LQDA?
No congressional trades found for this stock.